阿维莫泮与根治性膀胱切除术患者住院时间和住院费用降低相关
基于Premier医疗数据库2009至2015年数据,纳入1087例因膀胱癌行择期根治性膀胱切除术的患者,其中511例围手术期使用阿维莫泮。阿维莫泮与住院费用降低2709美元(95%CI:-4507至-912,P=.003)、中位住院时间缩短(7天 vs 8天,P<.001)及肠梗阻再入院几率降低(校正OR:0.63,P=.041)相关,且未增加主要并发症。
要点
- 阿维莫泮与根治性膀胱切除术患者住院费用降低2709美元相关。
- 阿维莫泮组中位住院时间7天,未使用组8天,差异有统计学意义。
- 阿维莫泮与肠梗阻再入院几率降低相关(校正OR:0.63,P=.041)。
核心结论
- 阿维莫泮与根治性膀胱切除术患者住院费用显著节省相关,常规使用可能是降低膀胱癌总体经济负担的成本效益策略。
研究设计与样本
- 回顾性队列研究,数据来自Premier Healthcare Database(全国性全支付方医院数据库),纳入2009至2015年因膀胱癌行择期根治性膀胱切除术的患者1087例,其中511例围手术期使用阿维莫泮。
主要发现
- 阿维莫泮与住院费用降低2709美元相关(95%CI:-4507至-912,P=.003)。
- 阿维莫泮与中位住院时间缩短相关(7天 vs 8天,P<.001)。
- 阿维莫泮与肠梗阻再入院几率降低相关(校正OR:0.63,P=.041)。
- 阿维莫泮组药房成本较高,但因住院时间缩短带来的较低食宿费用所抵消。
- 两组主要并发症无显著差异,结果在多个校正回归模型中稳健。
临床怎么用
- 对于因膀胱癌行根治性膀胱切除术的患者,围手术期可考虑使用阿维莫泮以缩短住院时间并降低住院费用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the impact of alvimopan in patient undergoing radical cystectomy (RC) for bladder cancer. We hypothesize that alvimopan can decrease cost for RC by reducing length of stay (LOS). METHODS: We identified patients who underwent elective RC for bladder cancer from 2009 to 2015 in the Premier Healthcare Database, a nationwide, all-payer hospital-based database, and compared patients who received and did not receive alvimopan in the perioperative period. Hospitals that had no record of administering alvimopan for patients undergoing RC were excluded. The primary outcomes were LOS and the direct hospital costs. The secondary outcomes were 90-day readmission for ileus and major complications. RESULTS: After applying the inclusion criteria, the study cohort consisted of 1087 patients with 511 patients receiving perioperative alvimopan. Alvimopan was associated with a reduction in hospital costs by -$2709 (95% confidence interval: -$4507 to -$912, P = .003), decreased median LOS (7 vs 8 days, P < .001), and lower likelihood of readmission for ileus (adjusted odds ratio: 0.63, P = .041). While alvimopan use led to higher pharmacy costs, this was outweighed by lower room and board costs due to the reduced LOS. There was no significant difference between 2 groups regarding major complications. These results were robust across multiple adjusted regression models. CONCLUSION: Our data show that alvimopan is associated with a substantial cost-saving in patients undergoing RC, and suggest that routine use of alvimopan may be a potential cost-effective strategy to reduce the overall financial burden of bladder cancer.
引用
- Huang JT, Cole AP, Mossanen M, et al. Alvimopan Is Associated With a Reduction in Length of Stay and Hospital Costs for Patients Undergoing Radical Cystectomy. Urology. 2020. PMID: 32268172. doi:10.1016/j.urology.2020.01.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。